117 related articles for article (PubMed ID: 16619562)
1. Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study.
Stathopoulos GP; Boulikas T; Kourvetaris A; Stathopoulos J
Anticancer Res; 2006; 26(2B):1489-93. PubMed ID: 16619562
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
[TBL] [Abstract][Full Text] [Related]
3. Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors.
Spunt SL; Freeman BB; Billups CA; McPherson V; Khan RB; Pratt CB; Stewart CF
J Clin Oncol; 2007 Jun; 25(16):2274-80. PubMed ID: 17538173
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical and pharmacological study of liposome-entrapped NDDP administered intrapleurally in patients with malignant pleural effusions.
Perez-Soler R; Shin DM; Siddik ZH; Murphy WK; Huber M; Lee SJ; Khokhar AR; Hong WK
Clin Cancer Res; 1997 Mar; 3(3):373-9. PubMed ID: 9815694
[TBL] [Abstract][Full Text] [Related]
5. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
[TBL] [Abstract][Full Text] [Related]
6. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of single-dose oxaliplatin in Japanese patients with malignant tumors.
Shirao K; Matsumura Y; Yamada Y; Muro K; Gotoh M; Boku N; Ohtsu A; Nagashima F; Sano Y; Mutoh M; Tanigawara Y
Jpn J Clin Oncol; 2006 May; 36(5):295-300. PubMed ID: 16702162
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
Campone M; Rademaker-Lakhai JM; Bennouna J; Howell SB; Nowotnik DP; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2007 Sep; 60(4):523-33. PubMed ID: 17308894
[TBL] [Abstract][Full Text] [Related]
9. UFT in combination with oxaliplatin: clinical phase I study in patients with advanced or metastatic solid tumors.
Sastre J; Aranda E; Abad A; Gallego J; Manzano JL; Gómez A; Carrato A; López E; Díaz-Rubio E;
Anticancer Drugs; 2006 Apr; 17(4):417-21. PubMed ID: 16549999
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer.
Zhu AX; Clark JW; Ryan DP; Meyerhardt JA; Enzinger PC; Earle CC; Fuchs CS; Regan E; Anbe H; Houghton M; Zhang J; Urrea P; Kulke MH
Cancer Chemother Pharmacol; 2007 Feb; 59(3):285-93. PubMed ID: 16786333
[TBL] [Abstract][Full Text] [Related]
11. A dose-escalation study of pegylated liposomal Doxorubicin and oxaliplatin in patients with advanced solid tumors.
Kotsakis A; Kouroussis Ch; Androulakis N; Agelaki S; Kalbakis K; Vamvakas L; Vardakis N; Kalykaki A; Polyzos A; Georgoulias V; Mavroudis D
Oncology; 2006; 71(3-4):190-6. PubMed ID: 17641537
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
; Ryan DP; Niedzwiecki D; Hollis D; Mediema BE; Wadler S; Tepper JE; Goldberg RM; Mayer RJ
J Clin Oncol; 2006 Jun; 24(16):2557-62. PubMed ID: 16636336
[TBL] [Abstract][Full Text] [Related]
14. [A dose escalation study of concurrent chemoradiation therapy with nedaplatin for cervical cancer].
Hatae M; Takahashi T; Kodama S; Nakayama H; Kuzuya K; Saji F; Kamiura S; Watanabe Y; Nishimura R; Kono I; Ariyosh Y; Fukuoka M; Imajo Y; Hasegawa K; Noda K; ;
Gan To Kagaku Ryoho; 2005 Apr; 32(4):473-8. PubMed ID: 15853213
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).
; Villablanca JG; Krailo MD; Ames MM; Reid JM; Reaman GH; Reynolds CP
J Clin Oncol; 2006 Jul; 24(21):3423-30. PubMed ID: 16849757
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study.
Ten Bokkel Huinink WW; Sufliarsky J; Smit WM; Spanik S; Wagnerova M; Hirte HW; Kaye S; Johri AR; Oza AM
J Clin Oncol; 2009 Jul; 27(19):3097-103. PubMed ID: 19451434
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses.
Tamura K; Nakagawa K; Kurata T; Satoh T; Nogami T; Takeda K; Mitsuoka S; Yoshimura N; Kudoh S; Negoro S; Fukuoka M
Cancer Chemother Pharmacol; 2007 Jul; 60(2):285-93. PubMed ID: 17136542
[TBL] [Abstract][Full Text] [Related]
18. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
19. Optimal dose-finding study of bi-weekly paclitaxel in unresectable advanced or recurrent gastric cancer.
Koizumi W; Tanabe S; Higuchi K; Sasaki T; Nakayama S; Nakatani K; Nishimura K; Shimoda T; Azuma M; Ishido K; Saigenji K
Anticancer Res; 2006; 26(5B):3797-802. PubMed ID: 17094404
[TBL] [Abstract][Full Text] [Related]
20. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
